# Study to Evaluate the Safety and Immunogenicity of Pandemic Monovalent (H5N1) Influenza Vaccines (Whole Virus Formulation) in Adults 18 and 60 Years of Age

> **NCT00309647** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 400 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Influenza Monovalent Whole virus (H5N1) adjuvanted vaccine
- **BIOLOGICAL:** Influenza Monovalent Whole virus (H5N1)

## Key facts

- **NCT ID:** NCT00309647
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03-29
- **Primary completion:** 2006-11-01
- **Final completion:** 2006-11-16
- **Target enrollment:** 400 (ACTUAL)
- **Last updated:** 2017-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00309647

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00309647, "Study to Evaluate the Safety and Immunogenicity of Pandemic Monovalent (H5N1) Influenza Vaccines (Whole Virus Formulation) in Adults 18 and 60 Years of Age". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00309647. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*